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Abstract
Background: Consider the problem of designing a panel of complex biomarkers to predict a patient’s health or
disease state when one can pair his or her current test sample, called a target sample, with the patient’s previously
acquired healthy sample, called a reference sample. As contrasted to a population averaged reference this reference
sample is individualized. Automated predictor algorithms that compare and contrast the paired samples to each
other could result in a new generation of test panels that compare to a person’s healthy reference to enhance
predictive accuracy. This paper develops such an individualized predictor and illustrates the added value of including
the healthy reference for design of predictive gene expression panels.
Results: The objective is to predict each subject’s state of infection, e.g., neither exposed nor infected, exposed but
not infected, pre-acute phase of infection, acute phase of infection, post-acute phase of infection. Using gene
microarray data collected in a large scale serially sampled respiratory virus challenge study we quantify the diagnostic
advantage of pairing a person’s baseline reference with his or her target sample. The full study consists of 2886
microarray chips assaying 12,023 genes of 151 human volunteer subjects under 4 different inoculation regimes (HRV,
RSV, H1N1, H3N2). We train (with cross-validation) reference-aided sparse multi-class classifier algorithms on this data
to show that inclusion of a subject’s reference sample can improve prediction accuracy by as much as 14 %, for the
H3N2 cohort, and by at least 6 %, for the H1N1 cohort. Remarkably, these gains in accuracy are achieved by using
smaller panels of genes, e.g., 39 % fewer for H3N2 and 31 % fewer for H1N1. The biomarkers selected by the predictors
fall into two categories: 1) contrasting genes that tend to differentially express between target and reference samples
over the population; 2) reinforcement genes that remain constant over the two samples, which function as
housekeeping normalization genes. Many of these genes are common to all 4 viruses and their roles in the predictor
elucidate the function that they play in differentiating the different states of host immune response.
Conclusions: If one uses a suitable mathematical prediction algorithm, inclusion of a healthy reference in biomarker
diagnostic testing can potentially improve accuracy of disease prediction with fewer biomarkers.
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Background
It is evident that that patient history can improve inter-
pretability of diagnostic data such as a panel of assayed
biomarkers. When this history includes a previously col-
lected assay, the assay constitutes a reference baseline
against which the current assay can be quantitatively com-
pared. However, as the size and complexity of clinical
biomarker panels increase, manual cross-assay compar-
isons become impractical. This motivates the develop-
ment of automated algorithms that can combine a current
target assay and a reference assay with improved pre-
diction or classification performance. In this paper we
consider the problem of using a panel of biomarkers to
predict a patient’s health state when both the target sam-
ple and reference sample are available. Two questions are
of interest. Can such a reference sample be used to more
accurately assess the deviation of the target sample from a
previously established patient baseline, potentially trans-
lating into improved predictions? Can such predictions
be performed accurately with relatively fewer biomark-
ers, i.e., a smaller test panel, potentially translating into
a less expensive test? In this paper we show that the
answer to both of these questions is affirmative. Using
a state-of-the-art multi-block sparse predictor algorithm,
and a large-scale serially sampled data set collected in
a human viral challenge study, we present an algorithm
for reference-aided health prediction that attains higher
predictive accuracy using a smaller panel of biomarkers.
The reader may not find it surprising that automated
diagnostics may benefit from pairing a reference sam-
ple and a target sample. Indeed, it has been common
clinical practice for a physician to manually compare a
small number of a patient’s analytes to his or her previ-
ous test results. However, such manual comparison will
become increasingly difficult as we enter the era of pre-
cision medicine where whole genome expression or next
generation sequencing platforms may play an important
clinical role [1–3]. In this era, automated algorithms will
be needed not only for accurate prediction but also for
selection of a suitably small subset of the thousands of
probes generated by these platforms. Such algorithms
impose sparsity on the predictor by utilizing only a small
fraction of the available probes. The reduction of the num-
ber of probes (genes) is relevant to personalized medicine
applications since it leads to a more economical (lower
complexity) targeted biomarker assay. Previous work has
developed such algorithms in the context of prediction
of acute respiratory virus infection [4–6]. This paper
goes one step further and shows that adding one healthy
reference sample can result in improved prediction
performance.
The paper is organized as follows. We first present
the formulation of our optimization problem in the
“Methods” section, including the loss function used as
surrogates in reference-based classification, the proper
regularization that selects variables relevant simultane-
ously to all classes and references, and followed by a
discussion about the general algorithm we propose to
solve the optimization. Then we present the performance
of the reference-based classification applied to H3N2,
H1N1, HRV, and RSV flu challenge data sets in the results
section. Advantages of the methods and biological inter-
pretation are presented in the discussion section. The
conclusion section concludes this paper.
Methods
The proposed reference-aided prediction method is based
on a state-of-the-art supervised multi-block multi-class
classifier algorithm with variable selection [7]. To illus-
trate the advantages of the proposed predictor, we will
demonstrate superior prediction performance on data
collected from large scale serially sampled respiratory
virus challenge studies. Data from the challenge studies
have previously been used by us and others to derive
molecular signatures for acute respiratory infection (ARI)
[4, 5, 8, 9]. This paper’s contribution is the introduction
of a new individualized reference-aided predictor that is
demonstrated on an extended set of data collected from
additional challenge studies (see Table 1). More details on
these challenge studies can be found in the aforememen-
tioned references and in the Additional file 1. We describe
the challenge studies first and then turn to the automated
predictor afterwards.
Viral challenge study model
To demonstrate the advantages of reference-based predic-
tion, we use data from a serially sampled challenge study.
The challenge study consists of a total of 151 subjects
(human volunteers) that, shortly after enrollment in the
study, were inoculated with sham or live virus from one of
4 categories of pathogen (HRV, RSV, H3N2, H1N1). The
overall study was conducted over a 4 year time period
in 7 stages (see Table 1 for a summary). Research par-
ticipants in these studies provided informed consent and
all research activities were conducted in accordance with
the Declaration of Helsinki and local policies and regula-
tions. These studies were approved by the DukeUniversity
Health System (DUHS) Institutional Review Board (IRB).
Where applicable, additional approval was obtained from
a local governing IRB where the study activities occurred:
Western Institutional Review Board (WIRB) and the Uni-
versity of Virginia IRB approved the studies that were
conducted Retroscreen Virology, London, UK and UVA,
respectively.
Each subject in the study was serially sampled for
several days quantifying time courses of whole blood
gene expression by Affymetrix Human U133A 2.0
GeneChips, self-reported clinical symptom scores over
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Table 1 Composition of data collected in the respiratory virus challenge study. The study enrolled a total of 151 subjects challenged
with 4 difference viruses over seven different challenge sub-studies and samples at multiple regularly spaced time points over a time
period ranging from 3–5 days. The first column is the sub-study designation. Second column is the virus used in the challenge. Third
and fourth columns are the year and location the sub-study was conducted. Fifth column is the DUHS IRB protocol number. Sixth
column is the duration of the sub-study in hours. Last two columns are the number of subjects and the number of time points
collected per subject, respectively
Challenge Virus Year Location IRB protocol Duration (hrs) # Subjects # Time points
DEE1 RSV 2008 Retroscreen Pro00002796 166 20 21
DEE2 H3N2 2009 Retroscreen Pro00006750 166 17 21
DEE3 H1N1 2009 Retroscreen Pro00018132 166 24 20
DEE4 H1N1 2010 Retroscreen Pro00019238 166 19 21
DEE5 H3N2 2011 Retroscreen Pro00029521 680 21 23
HRV UVA HRV 2008 Univ. of Virginia Pro00003477 120 20 15
HRV Duke HRV 2010 Duke Univ. Pro00022448 136 30 19
8-10 symptoms (varied by study), and viral shedding from
periodic nasopharyngeal titrations. The Affymetrix gene
probes were log transformed and normalized using the
RMA package with quantile normalization, median polish
and a custom cdf mapping from oligoprobes to gene yield-
ing 12,023 gene probes (see Additional file 1 for details
on genechip normalization and symptom symptom score
definitions).
Subjects were sampled at least once before the viral
inoculum was administered and at least 14 times after
inoculation. Each subject was designated as a symp-
tomatic subject (Sx) or an asymptomatic subject (Asx) and
as an infected subject (Inf ) or uninfected subject (UnInf).
The Asx/Sx designation was based on a modified Jackson
score computed from the self-reported clinical symptoms
[10, 11]. The Inf/UnInf designation was determined from
viral shedding data: a subject was declared infected if the
viral titers exceed a high threshold at any time point or if
they exceed a lower threshold at any tow time points. Fur-
ther details are provided in the Additional file 1 deposited
to the GEO database (accession number GSE73072).
For the prediction analysis, we excluded 44 clinically
ambiguous subjects due to inconsistencies between their
declared symptomatic status and measured shedding sta-
tus and 3 subjects that had no Affymetrix gene probes
collected. These 44 clinically ambiguous subjects were at
some time either acutely infected but asymptomatic or
not infected but acutely symptomatic. Thus the results
reported below are restricted to the 104 unambiguously
healthy (Asx and uninfected) and unambiguously ill (Sx
and infected) subjects. Of these 104 unambiguous sub-
jects 41 were infected subjects and 63 were uninfected
subjects, and they will be designated as such in the sequel.
For these 104 subjects five time-specific infection states
were determined on the basis of symptom scores and the
viral shedding measurements. State 1 is “baseline” before
inoculation. The other states occur after inoculation. State
2 is “Asx and UnInf” and applies to all post-inoculation
samples of the uninfected subjects. States 3, 4 and 5 occur
in the infected subjects after inoculation. State 3 is “Sx and
pre-acute Inf,” State 4 is “Sx and acute Inf,” and State 5 is
“Sx and post-acute Inf.” For each subject a healthy refer-
ence genechip sample was taken from baseline (state 1)
and paired with one of the post-inoculation genechip sam-
ples taken from the subject’s post-inoculation time course
(states 2-5). The state predictors, described below, were
trained and tested on subsets of these paired samples. The
5 state designations are illustrated in Fig. 2c for the H3N2
DEE2 cohort and in corresponding figures for the HRV,
RSV and H1N1 cohorts availabel on GEO (GSE73072).
The Additional file 1 also contains details about the data
collection and the criteria used for designating the states
from shedding and symptom score data.
Mathematically, we denote the i-th microarray sample
as the p = 12, 023 dimensional vector xi. The i-th sam-
ple is labeled as yi ∈ {1, 2, . . . ,K} corresponding to one of
the K = 4 possible infected/symptomatic states. The sub-
ject from whom the i-th sample was collected is denoted
as si ∈ {1, . . . ,m}, wherem is the total number of subjects.
Figure 1 illustrates the time vs. subject matrix layout of the
challenge study. The time instant labeled 0 (white vertical
line) corresponds to the time of inoculation. The loca-
tion of a hypothetical reference sample and target sample
for a given subject si is shown in the figure. For illustra-
tion, Fig. 2 shows the titration and symptom data collected
from subjects in the H3N2 DEE2 study. Similar figures for
the other studies, summarized in Table 1, are available on
GEO (GSE73072).
Prediction algorithms
To establish and quantify the value of including a sub-
ject’s reference sample, we implement a state-of-the-art
automated prediction algorithm that performs variable
selection and accomodates a reference sample in addition
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Fig. 1 Sample data layout for standard and reference-aided prediction. Each cell in this matrix corresponds to a sample xi of a subject si taken at
some time during the viral challenge study. The corresponding infection state label yi for each target sample xi is shown in Fig. 2.C for the particular
case of the H3N2 challenge study. The standard predictor tries to predict the state using only the target sample. The reference-aided predictor uses
both the target sample and the reference sample taken prior to inoculation time, denoted by the white vertical line
to a target sample. The predictor for the state yi is learned
from the biomarker data xi using a supervised sparse
multi-blockmulti-class classification algorithm, described
in detail below. The different classes classified by the algo-
rithm correspond to the different infection states. Sparsity
forces the algorithm to select a small number of biomark-
ers (genes) from the 12,023 possible biomarkers. The
imposition of sparsity is required in order to minimize
overfitting error since the number of samples available to
train the classifier is much smaller than the total num-
ber of biomarkers [12, 13]. The multi-block structure is
used to force the reference-aided classifier to use the
same subset of biomarkers for the paired reference and
target samples in the classifier function. More specifi-
cally, as discussed below, for the reference-aided predictor
there are two blocks corresponding to, respectively, the
gene probe values in the reference sample and the tar-
get sample. For the standard predictor there is only one
block corresponding to the gene probe values of the target
sample.
A classifier is a function that operates on a data point x
(the input) and produces a decision yˆ (the output) about
the class, where yˆ ∈ {1, . . . ,K}. In machine learning
the classifier function is optimized to achieve the best
possible classification accuracy over a set of training sam-
ples {xi, yi}ni=1, which are typically a subset (the training
set) of all the available data. The result of this optimiza-
tion is often averaged over many different training subsets
of the data, e.g., by random resampling or leave-one-
out resampling, a process called classifier cross-validation
[12]. Among the many different algorithms available for
multi-class classification the support vector machine
(SVM) is one of the most prevalent. There are two com-
mon strategies for multi-class classification that have
been proposed: (1) solving the multi-class problem by a
series of binary SVM classifiers [14, 15]; (2) formulating
a single unified multi-class SVM [16–21]. In this paper
we adopt the latter more direct approach to multi-class
classification.
As described in [19], the unified K-class classifier is a
scoring based algorithm that classifies the input by com-
puting its score for each class and outputs the class label
associated with the maximum score. Specifically, given K
functions f1, . . . , fK the unified K-class classifier outputs
the decision yˆ = argmaxk fk(x) These functions assign
confidence scores to the input x and can be chosen as
linear functions of the form
fk(x) = wkTx + bk , k = 1, . . . ,K (1)
where wk ∈ Rp is a (column) vector of p weights {wki}pi=1
and bk ∈ R is a scalar offset. While other forms of the
score functions are also common, e.g., kernelized linear,
polynomial or sigmoidal functions, we will use the linear
function (1) to design both the standard and reference-
aided predictor.
Since there are many fewer samples (n) than variables
(p) it is desirable to reduce the number of biomarkers used
by the classifier in order to minimize overfitting errors
[12]. This can be accomplished by constraining the weight
vectors {wk}Kk=1 to have common sparsity, i.e., the wk’s
have many common entries equal to zero. Defining the
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Fig. 2 H3N2 DEE2 challenge study viral shedding map (a), symptom score map (b), infection state map (a). a shows viral titration measurements for
each subject at each sample time. b shows the sum of the 10 self-reported symptom scores. We use the measurements in A and B to designate
each subject as infected (Inf), noninfected (UnInf), symptomatic (Sx), or asymptomatic (Asx). The subject dedignations can be found in the
Additional file 1. Subjects whose titer scores and symptom scores agree, i.e., those who are either infected and symptomatic or uninfected and
asymptomatic, are used for training the predictors. We assign 5 state labels to these subjects, as shown in (c), that correspond to baseline reference
(state 1), UnInf (state 2), pre-accute Inf (state 3), acute Inf (state 4), and post-acute Inf (state 5). The onset and offset time of detectable titration are
used to set the boundaries between class 3 and 4 and class 4 and 5 respectively (see Additional file 1)
K × p weight matrix W =[w1, . . . ,wK]T and K-element
vector b = [b1, . . . ,bK]T, this common sparsity constraint
is expressed as W having many columns identically equal
to zero. This is a form of structured sparsity [22], also
called group sparsity, that is mathematically expressed
as the “mixed 1/0 norm” constraint on W: ‖W‖1,0 =∑p
j=1 ‖w(j)‖0 ≤ q, where q is much less than p, w(j) is
the j-th column of W and ‖u‖0 is a function that counts
the number of non-zeros in a K-element vector u. A con-
vex relaxation of this constraint, adopted for the classifier
used in this paper, is the mixed 1/2 norm constraint
[7, 23]:
R(W) = ‖W‖1,2 =
p∑
j=1
‖w(j)‖2 ≤ q, (2)
where ‖u‖22 =
∑K
k=1 u2k denotes the 2 or Euclidean norm
of u.
To specify the unified multiclass classifier it therefore
suffices to select the sparse weightsW and offsets b defin-
ing (1). These are learned from the data by solving the







V (W,b, xi, yi) + λR(W), (3)
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where R(W) = ‖W‖1,2 is the relaxed group sparsity
inducing regularization function (2), λ > 0 is a regular-
ization parameter, and V (W,b, xi, yi) is an empirical loss
function, depending on the parameters and the training
data {xi, yi}ni=1, that penalizes errors between the classifier
output yˆi and the true class label yi.
As contrasted to the standard multi-class classifier,
developed above, the reference-aided multi-class classi-
fier uses a higher dimensional subject-specific input xs,
which is a 2p-dimensional vector, constructed by concate-
nating the paired reference and target samples of subject
s, denoted xrefs ) and xtargets , into a single vector. Note that
the j-th and (j + p)-th elements of the vector xs cor-
respond to the same biomarker (gene probe). With the
subject-specific input xs the weightmatrixW of themulti-
class classifier is K × 2p dimensional. Figure 3 illustrates
the group sparsity constraint that enforces that W select
only a few common biomarker variables from each pair.
Such sparsity structure can be induced into the predictor
by modifying the penalty function in (3) from the mixed













Both the standard and the reference-aided multi-class
classifier are learned by minimizing a risk function of the
form (3). For the purposes of this paper, we adopt the
multi-class hinge loss function V (W,b, {xi, yi}) proposed
in [19] which, along with the proposed mixed 1/2 norm
sparsity penalty R, makes (3) a convex but non-smooth
optimization problem. This problem can be solved with
iterative optimization methods and we use an optimiza-
tion algorithm, developed in [7, 23], that is based on
variable splitting [24]. The optimization algorithm used in
this paper is given as Algorithm 3.
A two-stage adaptive group sparsity method was used
to further reduce the danger over-fitting in training the
classifier. This method is an extension of the adaptive
lasso [25, 26] to the group sparse multi-class classification
framework developed above. The method is implemented
as follows. Suppose after solving (3) we have an initial esti-
mate Winit,b of the classifier parameters. Then we refine
this estimate by solving (3) once more, except in place of






for the standard classifier. A two-stage adaptive reference-
aided classifier is defined similarly except that in the
summand defining Radapt the weights w(j) and winit,(j) are
respectively replaced by w˜(j) and w˜init,(j).
Algorithm 1: Reference-aided classification algorithm.
The algorithm minimizes the convex mixed 1/2
mixed norm sparsity penalized empirical risk (3) by
applying variable splitting in an ADMM framework
[24]. The minimization step 3 is solved by sequential
dual method discussed in [27, 28] and the minimiza-
tion step 5 is solved non-iteratively by applying the
proximal operator for the mixed 1/2 norm [29]. The
parameters λ andμ are user-defined tuning parameters
that control the column-sparsity of W and the conver-
gence rate, respectively. In the experiments conducted
in this paper, λ is selected by cross-validation,μ is fixed
to be 10
1 set τ = 0, choose μ > 0,M0,W0, D0
2 while stopping criterion is not satisfied do






ξi + μ2 ||W − Mτ − Dτ ||2F
4 s.t. ∀i, k (wTyixi + byi) + δyi ,k − (wTk xi + bk) ≥ 1 − ξi





||m˜(j)||2 + μ2 ||Wτ+1 −M−Dτ ||2F
6 Dτ+1 = Dτ − Wτ+1 + Mτ+1
7 τ = τ + 1
Fig. 3Multi-block group sparsity structure for proposed reference-based predictor. A multi-block multi-class classifier of K = 3 classes applies a
K × 2pmatrixW =[W(ref),W(target)] to the combined vector of probes on reference and target gene chips in order to form the vector of scores
for each of the K = 3 states. The two blocks of the classifier correspond to the block of weightsW(ref), applied to the reference sample, and the
block of weightsW(target), applied to the target sample. The classifier decision rule is to assign the state label that corresonds to the maximum
score. The blocks share sparsity, denoted by the black columns in the weight matrix, which designate columns that are identically zero. Variables
associated with these zero columns are not selected by the classifier
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Results
Here we demonstrate that the reference-based predictor
described in theMethods section results in improved state
classification accuracy with a smaller panel of biomarkers
for the challenge study dataset studied. The standard and
reference-aided predictors were trained and tested sepa-
rately on data from each virus category. These data are
denoted H3N2, H1N1, HRV and RSV, respectively, for the
pooled data from the two H3N2 studies, the pooled data
from the two H1N1 studies, the pooled data from the two
HRV studies, and the data from the single RSV study (see
Table 1). These four virus-specific datasets consisted of
m = 29, 24, 31, 17 subjects, respectively. Each of the virus-
specific datasets was divided into m training-test parti-
tions containingm−1 subjects for training by successively
removing subjects one at a time for testing (leave-one-out
partitions). For each of these subsets the predictors were
trained by minimization of the empirical risk (3), using
2-fold cross-validation to first select the regularization
parameter λ with the mixed norm sparsity constraint R,
and an additional 2-fold cross-validation to select the reg-
ularization parameter with the adaptive sparsity inducing
regularizers Radapt discussed at the end of the Methods
section on Prediction algorithms. The prediction perfor-
mance and variable selection frequencies were assessed
by averaging the predictor’s state misclassification errors
over them training-test partitions.
Furthermore, each of the variables in each training set
was standardized to z-scores by subtracting the sam-
ple mean and dividing by the sample standard deviation,
where these sample statistics were computed over the
samples in the training set. The biomarkers of each sub-
ject in the each test set were standardized using the sample
mean and standard deviation computed from the associ-
ated training set. To reduce possible bias due to imbalance
in the numbers of samples across classes (states), at each
training iteration we applied uneven cost to each sam-
ple such that the average sampling proportions among the
classes were identical.
The accuracy of the reference-aided predictor is pre-
sented in row 1 of Table 2 for each of the four virus-
specific datasets. For comparison the accuracy of three
other predictors is shown in the remaining rows of Table 2.
The proposed reference-aided predictor achieves bet-
ter performance in terms of average error rates. This
improvement is achieved using biomarker panels with sig-
nificantly fewer genes, as compared to the standard pre-
dictor in row 2 of Table 2. The number of genes selected
by the standard predictor was optimized by the two-stage
adaptive cross-validation procedure described in Section
Methods. Row 3 shows the performance of a constrained
standard predictor when the regularization parameter is
selected so that it uses approximately the same num-
ber of genes as the proposed reference-aided predictor.
Table 2 Average accuracy (error rate) and average size of the
gene panel (number of selected genes) selected by automated
predictors of infected state (class) for different viral challenges
(data from DEE2/DEE5, DEE3/DEE4 and HRV-UVA/HRV-Duke were
pooled and designated as H3N2, H1N1, and HRV in table). Shown
are the reference-aided predictor (w/ baseline reference), the
standard predictor (w/o baseline reference), the standard
predictor with constraints to have the similar complexity in terms
of the number of genes as the reference-aided predictor
(constrained standard predictor), and the differential predictor.
Across all viruses the inclusion of the baseline reference results in
a decrease in error rate and a reduction in the number of genes
used by the predictor. The reported accuracy and size of panel
were computed by cross-validation of the predictors using
leave-one-subject-out resampling to partition the data into
training and target samples
Virus H3N2 H1N1 HRV RSV
Classes 2345 2345 2345 234
w/ baseline reference
Error rate 0.386 0.480 0.483 0.635
Number of selected genes 200.34 287.54 287.55 238.53
w/o baseline reference
Error rate 0.448 0.508 0.526 0.728
Number of selected genes 327.90 420.25 358.48 593.82
Constrained standard predictor
Error rate 0.458 0.517 0.544 0.737
Number of selected genes 207.38 271.83 298.00 243.29
Differential predictor
Error rate 0.415 0.492 0.571 0.678
Number of selected genes 481.48 1209.46 464.39 503.29
The actual genes selected by this constrained predictor
differ from those slected by the reference-aided predic-
tor and the performance is significantly worse than the
unconstrained predictor in row 2. Row 4 shows the perfor-
mance of a differential predictor that is implemented by
applying the standard predictor to the difference between
target and reference sample xtargets − xrefs . This differential
predictor is implemented by restricting the reference-
aided predictor to the case where the reference and target
weights have identical magnitudes but opposite signs. The
performance in row 4 of Table is better than that of the
standard predictors (rows 2 and 3) but worse than that of
the proposed predictor (row 1). This indicates that simple
differencing of the target and reference samples, corre-
sponding to using all probes as contrast genes and none
as reinforcement genes, leads to a less effective predictor
than the one proposed in row 1 of Table 2.
The per-chip misclassification error rates, computed
by aggregating over the m training-test partitions, are
shown in Fig. 4 as heatmaps over times and subjects for
each virus-specific dataset. Figures 4 and 5 show that
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Fig. 4 Heatmaps of predictor error rates for H3N2 DEE2 dataset. The heatmaps of the sample-specific predictor error rate for classifying states 2,3,4
and 5, defined in Fig. 2, for samples in the H3N2 DEE2 dataset. The top figure (a) shows the error rates of the standard predictor (no reference). The
bottom figure (b) show the corresponding results of the reference-aided predictor
the proposed reference-aided predictor achieves the most
improvement in predicting states 2 (UnInf) and 3 (pre-
acute Inf ), which are the most difficult states to classify.
The different roles of the biomarkers that were
automatically selected by the reference-aided predic-
tor yields insight into these accuracy improvements.
For concreteness, we focus on the H3N2 dataset. See
Additional file 1 for analysis of the biomarkers selected
in the HRV, RSV and H1N1 datasets. The variables that
were frequently selected by the reference-aided predic-
tors are shown in Fig. 6a for H3N2. The genes in this
figure were selected with frequency at least 70 %; i.e., they
were included in the trained reference-aided classifier in
at least 70 % of the training-test partition sets. The genes
are ordered according to the cluster order illustrated in
panel B. The bars in Fig. 6a represent the average value
of the weight w(ref ) applied to a specific gene in the ref-
erence sample (R), denoted as yellow bar, and the weight
w(target) applied to the same gene in the target sample
(T), denoted as a green bar. These selected biomarkers
can be grouped into two categories: (1) contrasting genes
(R and T weights have opposite sign); and (2) reinforcing
genes (R and T weights have the same sign). Contrasting
genes are selected by the predictor for their differential
expression between R and T, while reinforcing genes do
not differentially express but rather serve to normalize
the other variables (recall that the gene probes were log
transformed in the RMA normalization).
An example of a contrasting gene is the interferon
induced gene IFI27 which differentially expresses between
R and T for states 2, 3, 4 and 5. Interestingly, the signs of
the R and T weights for IFI27 are reversed in the score
function for state 2 (UnInf) as compared to their signs
for the score functions of the other three states (pre-acute
Inf, acute-Inf, post-acute Inf ): a relative decrease in IFI27
from reference to target sample induces a high UnInf
score while a relative increase induces a high Inf score.
An example of a reinforcing gene is the immunoglobin
lambda variable IGLV3-25 that plays the role of reinforc-
ing the UnInf state (positive contribution to state 2 score)
to the detriment of the Inf states (negative contributions to
state 3, 4, 5 scores). Another example, that reinforces the
Inf states instead of the UnInf state, is the NEDD4 binding
protein gene N4BP3. Note that some genes, e.g., PEX13
and LOC26010, take on a contrast role for some states
while they take on a normalizing role for other states.
Many of the genes that were selected by the reference-
aided predictor were not selected by other predictors










Fig. 5 Heatmaps of predictor error rates for H3N2 DEE2 dataset. The heatmaps of the sample-specific predictor error rate for classifying states 2,3,4
and 5, defined in Fig. 2, for samples in the H3N2 DEE2 dataset. The figure shows the difference between the error rates of the standard predictor (no
reference) and the error rates of the reference-aided predictor (with reference) for H3N2 DEE2. The entries in red have higher error rate using the
standard predictor than the reference-aided predictor, and vice versa
studied in Table 2. (See Sec. 4.1 in Additional file 1). Since
the differential predictor can only form contrasts between
reference and target gene probes none of the reinforcing
genes. Indeed, we did not find the reinforcing genes, e.g.,
IGVL3-25, NBP3 andMYOM2were selected by the differ-
ential predictor. The lack of reinforcement genes deprives
the differential classifier of potential normalizing variables
leading to poorer performance.
The average expression levels over time of the frequently
selected H3N2 genes shown in Fig. 6a are shown as
heatmaps in Fig. 6b, where the expression levels are aver-
aged over the uninfected and infected subjects, respec-
tively, in the left and right heatmaps. Notice that the
reinforcing genes, such as IGVL3-25, NBP3 andMYOM2,
appear to be related to susceptibility since the expression
levels are substantially higher or lower in the uninfected
population than in the infected population, even before
viral inoculation. The expression levels of contrast genes
such as IFI27, PEX13 and LOC26010, are relatively sta-
ble in the uninfected subjects but rapidly increase as an
infected subject enters the acute Inf phase (roughly 40 h
after inoculation).
The improved accuracy of the reference-aided predic-
tor can be visualized by rendering a scatter plot of the
vector of confidence scores, defined in (1), over all of the
samples. In Fig. 7 the scatterplot of the K = 3 dimen-
sional vector of scores is shown for the H3N2 pooled
challenge studies. In the scatterplot each of these vec-
tors has been given a different color depending on the
state of the particular target sample at which the score is
evaluated. The right panel of Fig. 7 shows the scatterplot
of confidence scores computed with the classifier weight
matrixW by reference-aided predictor, averaged over the
m training-test partitions. The left panel shows the asso-
ciated scatterplot for the standard predictor, implemented
with the average weights. Notice that the scores are better
separated when the references are taken into account.
Note that both with and without reference-aided training,
among all pairs of states, discrimination between state 3
(pre-infection) and state 4 (acute infection) is themost dif-
ficult. This is explained by the fact that states 3 and 4 apply
to the same group of subjects, namely, those that develop
acute symptomatic infection with significant levels of viral
shedding. For these subjects the ARI signature is develop-
ing during state 3 and comes into full bloom during state
4, thus making these states more similar to each other.
There are common genes in the four sets of biomark-
ers selected by the predictors trained separately on the
HRV, RSV, H3N2, and H1N1 viral-specific datasets. We
call these common biomarkers pan-viral predictive genes.
A Venn diagram of all the biomarkers that have been
found in each virus study is shown in Fig. 8, and the
pan-viral predictive genes in the intersection among all of
the studies are listed in Table 3. Heatmaps, analogous to
those shown in the H3N2 heatmap Fig. 6b, are shown for
these pan-viral predictive genes in Fig. 9 for all 4 viral-
specific datasets. Similarly to the H3N2 heatmap, some
genes seem to have a reinforcement role, such as C7orf58,
and others have a contrasting role, such as IFI27.
Discussion
The proposed reference-aided predictor significantly out-
performed the standard predictor that does not use the
reference, implemented with a single block multi-class
classification algorithm. Specifically, the reference-aided
predictor achieved an average (cross-validated) state pre-
diction accuracy improvement of: 14 % for RSV, 13 %
for H3N2, 9 % for HRV, and 6 % for H1N1. Remarkably,
for all of these viral challenges this gain in accuracy was
achieved with a smaller panel of genes: 60 % fewer for
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Fig. 6 Biomarkers selected by reference-aided predictor. The top figures in (a) show the genes selected by the proposed reference-aided predictor
with selection frequency≥ 70 % for the 4 different score functions for states 2,3,4,5. The value of the classifier weights for each of the score functions
are shown as yellow bars (weights applied to reference sample R) and green bars (weights applied to target sample T). Note that genes having
yellow and green bars of opposite sign are contrasting information in R vs T while genes having these bars with the same sign are reinforcing
information in R and T. The bottom figures in (b) show the expression of the genes shown in (a) averaged over the uninfected subjects (left) and
infected subjects (right). The expression levels are normalized such that the maximum and minimum of each gene achieve 1 and −1 respectively.
Let the averaged expression at time t be z(t), the maximum of z(t) be zmax , and the minimum be zmax . The normalized expression levels are
computed as z˜(t) = 2 × [z(t) − 0.5 × (zmax + zmin)] /(zmax − zmin)
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RSV, 39 % fewer form H3N2, 20 % fewer for HRV, and
31 % fewer for H1N1, as shown in Table 3. This sug-
gests that by including such a reference sample with the
target sample, the reference-aided predictor can build a
more parsimonious description of the infected vs unin-
fected phenotypes. As seen in the previous section, this
better description translates into improved prediction of
infection state. There are several possible reasons that
the reference-aided predictor achieves improvement in
accuracy while using significantly fewer predictor vari-
ables. First, by pairing an individual’s target sample to
his baseline reference sample, the reference-aided predic-
tor turns the standard predictor into an individualized
predictor. Second, the availability of a baseline sample
allows the predictor to learn genes that display a contrast
between an individual’s healthy baseline and sick target
samples. Third, even though the reference-aided predic-
tor has to learn twice as many coefficients, our predictor
sparsity penalty forces most of these to zero, resulting in
a more parsimonious predictor that minimizes overfitting
errors.
Moreover, many of the genes in the panels selected by
the automated reference-aided predictor and the stan-
dard predictor were different. The genes in the standard
predictor were similar to the acute respiratory infec-
tion (ARI) signature reported in [4]. The reference-aided
predictor selected a panel of genes that fall into two
classes: 1) contrast genes that exploit the fact the the
baseline reference differs significantly from the target
sample; 2) reinforcement genes that do not differ signif-
icantly but are used by the classifier for baseline nor-
malization. Specifically, for a contrast gene, the predictor
forms a weighted average of the baseline and target
expression levels using two coefficients having opposite
sign. For a reinforcement gene these two coefficients
have the same sign. We caution that these definitions
only make sense when the two coefficients have similar
magnitudes.
The reference-aided predictor identified the pan-viral
predictive genes as some of the best subject-specific
genes that either reinforce or contrast expression in the
subject’s reference and target samples. Many of these
genes are not included in the standard predictor that
does not use a reference. Table 3) indicates that the
reference-aided predictor found 8 pan-viral predictive
genes (C7orf58, CCR1, IFITM3, MTMR12, NUDT13,
ORM2, TSPAN8, and TSTAT3) that were not found by
the standard predictor. While some of these are orthologs
to genes in the standard predictor, others might rep-
resent additional pathways that can only be picked up
by analysis of paired samples. For example, some stud-
ies suggest that IFITM3 is important for intrinsic viral
resistance. Specifically, in vitro studies show that many
pathogenic viruses’ replication can be restricted by genes
in the interferon inducible transmembrane (IFITM) pro-
tein family, and it has been found that IFITM3 plays an
important role in the host’s defense against influenza A
virus [30]. Furthermore, it has been reported that dur-
ing RSV infection deletion of CCR1 leads to attenuated
pathophysiologic responses [31] and, as reported by the
NCBI gene database, an important acute phase plasma
protein is encoded by orosomucoid 2 (ORM2), which
can be stimulated during acute inflammation and be may
an important factor in immunosuppression. Other genes
among the 8 genes specific to the reference-aided pre-
dictor have no obvious function in immune response but
appear to have been selected to serve as normalization
genes.
Fig. 7 Scatter plots of the vector of scores over the H3N2 samples. Shown are scatterplots of the score functions in the multi-class classifier evaluated
for the standard predictor (w/o reference) at left and for the reference-aided predictor (w reference) at right. Points with a particular denote the
vector of scores for states 2, 3, and 4 for samples labeled with a particular state. The scores are better separated when the references are taken into
account. Especially note that the class 2 (UnInf) scores (labeled in blue) are much better separated
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Fig. 8 Venn diagram of the genes selected in HRV, RSV, H3N2 and H1N1 datasets. Indicated are the intersections of the genes that were selected at
least once by the standard predictor (left) and reference-aided predictor (right) in each of the virus-specific datasets. The list of the genes in the
intersection among all 4 datasets is listed in Table 3. These are called pan-viral predictive genes
Many of the genes that were selected by both the pre-
dictors (with and without baseline reference) are well
known transcription factors in host immune response.
Specifically, interferon-stimulated genes, such as IFI44L,
produce cellular factors that protect cells against invad-
ing viral pathogens [32]. OAS1 has been identified to
be relevant to apoptosis, which eliminates the cells that
have damaged DNA or have experienced uncontrolled
proliferation [33]. Therefore, it may prevent viral replica-
tion by eliminating virus-infected cells. Indeed we observe
the steady up-regulation of OAS1 during acute-infection.
Table 3 Biomarkers that have been selected in every virus study.
Notice that these genes are in the intersection among the 4 virus
studies in Fig. 8
Method Genes
w/o baseline reference ACP2 ADM AFFX-r2-Bs-dap-3_at
AMFR ASGR2 ATP9A BAIAP3
BTN2A2 C4BPA CDC20 CHI3L1
CYP26B1 DAP DCXR DSP EIF2AK2
ERC1 FBXL8 FOLR3 GDF9 H1F0
HMBOX1 HPCAL4 HRASLS3 IFI27
IFI44 IFI44L IFIT1 IFIT3 IGFBP6
IGFBP7 IGHV1-69 IGLV4-60 IL1F9
IRF5 IRF9 ISG15 LOC643224 LY6E
MAP7 MFAP3 MICB MMP1 MX1
MYOM1 NARFL NGFRAP1 NKX3-1
NQO2 NUDT4 OAS1 OLFM1 PAPSS2
PGGT1B PODXL PRRG4 PRSS21
RGS20 RIMBP2 RSAD2 SCO2 SERGEF
SERPINE2 SLC30A4 SP100 SPATA20
STAT1 TCL1B TMEM140 TNNT1
TSPAN15 TTLL4 TUBB6 UAP1L1
ZNF701
w/ baseline reference C7orf58 CCR1 H1F0 IFI27 IFI44L
IFITM3 IL1F9 IRF9 ISG15 MTMR12
NUDT13 OAS1 ORM2 RSAD2 STAT1
TSPAN8 TSTA3
The role of ISG15 in innate immunity to viral infec-
tion has been studied in [34], and has been found to be
highly expressed upon viral infection. IL1F9 is reported
in [35] to be be up-regulated in cells involved in immune
responses induced by HRV. IRF9 is one of the tran-
scriptional activators, along with STAT1 in the ISGF3
transcriptional complex, which stimulates the expression
of the interferon-inducible genes, e.g., IRF7 for antivi-
ral responses [36]. IRF7 is one of the interferon regula-
tory factors, which regulates transcriptional activities to
induce cellular response to the invasion of viruses. It has
been reported to induce the interferon inducible genes
like IFI27 in infected cells [37, 38]. Further studies suggest
that IRF7 controls both the innate immunity and adap-
tive immunity [39, 40]. Several of the pan-viral predictive
genes, e.g, IFI44L, IFI27, and OAS1 are related to type-
I interferon antiviral response, and have been reported
to constitute pathways regulating inflammatory response
[5, 41–43].
In this paper, several viral challenge study datasets
were used to demonstrate the intrinsic value of the pro-
posed reference-aided method for biomarker selection
and improved performance in predicting symptomatic
infection. These findings are, of course, specific to the
setting of our challenge studies and the value for clini-
cal applications needs to be further explored. Two issues
stand in the way of direct generalization of our findings to
clinical medicine.
The first issue is that each enrolled subject’s healthy
reference sample was collected within 24 h of exposure
to the viral pathogen. An open question is whether the
demonstrated performance advantages of the proposed
method would generalize to the clinically relevant case
where the reference sample collected in the more distant
past. Such a generalization will require testing ourmethod
on observational data collected over a longer baseline









Fig. 9 Expression profiles of reference-aided pan-viral predictive genes. Average expression profiles of the pan-viral predictive genes discovered by
the reference-aided predictor (genes listed at bottom of Table 3) averaged over the uninfected subjects (left) and infected subjects (right) in each
virus-specific dataset (a H3N2, b H1N1, c HRV, and d RSV). The expression levels are normalized such that the maximum and minimum of each gene
achieve 1 and −1 respectively
period than 24 h prior to exposure. Given the expanding
interest in discovery of temporal pathways for processes
such as biochronicity, immunity, and aging, we can antic-
ipate that such data will become available in the not so
distant future.
The second issue is that the findings reported here
are restricted to the subset of enrolled individuals who
unambiguously reported health or illness, as measured
by concordance between viral shedding and self-reported
symptoms. All predictors have low average accuracy when
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ambiguous reports are included in the training data, even
though the proposed reference-aided predictor maintains
significant performance advantages over the other predic-
tors to classify the state of infection (see Additional file 1:
Sec. 5 for details). This poor performance on ambiguous
subjects may signal the need for more complex non-linear
modeling of gene expression for these subjects. On the
other hand, such ambiguities may simply reflect the inad-
equacy of viral shedding and self reported symptom as
reliable proxies for symptomatic illness.
In spite of these caveats, the framework presented
here may be relevant to personalized medicine, where
preventative and diagnostic medical testing could pos-
sibly benefit from availability of a recent personalized
baseline reference. The reported results establish that,
when used with a carefully designed classifier, inclusion
of such a reference can improve the accuracy of classi-
fiers of early onset infection based on gene expression
assays. Furthermore, the variables selected by the pre-
dictor can give insight into the molecular discriminants
that provide high contrast between healthy baseline and
infection states. The referenced-based classifier frame-
work we have developed can likely be extended to other
diseases and diagnostic tasks, e.g., classifiying yellow fever
[44, 45] or personal health monitoring [5]. For exam-
ple, in a recently published paper by Chen et al. [46],
the authors have demonstrated the ability of a personal
‘omics’ profile to reveal dynamic molecular and medi-
cal phenotypes by monitoring a single individual over
14 months. This might be modeled by our multi-block
multi-class classifier framework, where the blocks parti-
tion the periods of health and sickness and the classes
indicate different stages of infection and/or types of
infection. The accuracy of such a multi-block classifier
might also benefit from integration of other biomark-
ers, e.g., proteomic, metabolomic, antibody, into the
predictor.
Conclusions
This paper developed reference-aided prediction as way to
design personalized test panels and associated predictors
when one can pair a target sample with a baseline ref-
erence sample from the same subject. The framework
is applicable when a population of serial samples from
multiple subjects are available. The proposed referenced-
aided predictor uses the framework of learning sparse
linear score functions in a multi-block multi-class support
vectormachine (SVM). However, other types of reference-
aided predictors may also be worth investigating, e.g.,
using multi-block non-linear kernelized multi-class clas-
sifiers or multinomial logistic classifiers.
We used a large-scale respiratory virus challenge study
to illustrate the advantages of reference-aided predic-
tion. In this predictive health problem, pre-inoculation
reference (baseline) samples of each subject are incor-
porated into the classifier along with post-inoculation
target samples. Application of the reference-aided predic-
tor demonstrated significant improvement in the accu-
racy of prediction of different stages of host immune
response for infected and uninfected subjects. Further-
more, it achieved this improved accuracy using fewer
biomarkers than a standard predictor that does not use a
reference sample. Some of the biomarkers discovered by
the reference-aided predictor are genes that exhibit high
contrast in expression between the target and reference
samples. Other biomarkers were discovered to be low con-
trast genes that use the reference sample to normalize the
target sample.
Withminormodification, the prediction algorithm used
in this paper applies tomore general serially sampled diag-
nostic tests than the single-reference/single-target pre-
dictor. For example, consider a predictor that labels the
state of a particular subject at the time a target sample
is acquired using both the target sample and at least one
previously acquired sample. This framework is applica-
ble to a wide range of applications in diagnostic medicine,
drug discovery and biology. For example, when using a
panel of biomarkers to test for health or disease of the sub-
ject, the anterior samples might correspond to the same
panel taken when the subject was at a baseline of health.
When testing for the specific stage of an advancing dis-
ease the anterior samples may be panels of previously
acquired target samples. It is likely that in these situations,
reference-aided predictors will similarly show accuracy
benefits.
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